BANDAR ENTERPRISES LLC SERIES 1 ASSURITY LABS
6140 S FORT APACHE ROAD SUITE #140, LAS VEGAS, NV 89148
NPI Number
1003244880
Practice location · View on Google Maps
SOS Verification: Pending Review
Multiple SOS Matches
Total Medicaid Payments
$2,117,226
-47% vs specialty average
Patients Seen
32,124
Total Claims
53,908
$ Per Patient
$66
Specialty avg: $9
Specialty Rank
#9 of 34
Clinical Medical Laboratory providers in Nevada
Peer Average
$3,969,875
Average total for Clinical Medical Laboratory
Claims per Patient
1.7
Average visits / services per person
Payments by Year
How much Medicaid paid this provider each year. Large jumps can indicate changes in practice volume or billing patterns.
| Year | Total Paid | % of Max |
|---|---|---|
| 2018 | $308,666 | |
| 2019 | $135,004 | |
| 2020 | $225,485 | |
| 2021 | $369,257 | |
| 2022 | $885,119 | |
| 2023 | $193,694 |
Procedure Code Breakdown
The specific medical services this provider billed Medicaid for. Each HCPCS/CPT code represents a different type of visit, test, or treatment.
| HCPCS Code | Description | Claims | Paid | % of Total | Avg per Claim |
|---|---|---|---|---|---|
| U0004 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 27,163 | $1,499,440 | 70.8% | $55 |
| G0483 | Advanced drug testing — checking for 22 or more types of drugs in urine or blood | 5,272 | $478,207 | 22.6% | $91 |
| U0005 | Infectious agent detection by nucleic acid (dna or rna); severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), amplified probe technique, cdc or non-cdc | 16,163 | $65,909 | 3.1% | $4 |
| 80307 | Drug test — checking urine or blood for multiple types of drugs | 1,901 | $37,794 | 1.8% | $20 |
| 87635 | Microbiology test — checking for infections (bacteria, viruses, fungi) | 334 | $15,357 | 0.7% | $46 |
| G0480 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including | 317 | $13,901 | 0.7% | $44 |
| 87798 | Microbiology test — checking for infections (bacteria, viruses, fungi) | 65 | $2,250 | 0.1% | $35 |
| G2023 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]), any specimen source | 2,230 | $2,081 | 0.1% | $1 |
| 87541 | Microbiology test — checking for infections (bacteria, viruses, fungi) | 65 | $575 | 0.0% | $9 |
| 87640 | Microbiology test — checking for infections (bacteria, viruses, fungi) | 65 | $575 | 0.0% | $9 |
| 87581 | Microbiology test — checking for infections (bacteria, viruses, fungi) | 65 | $575 | 0.0% | $9 |
| U0002 | 2019-ncov coronavirus, sars-cov-2/2019-ncov (covid-19), any technique, multiple types or subtypes (includes all targets), non-cdc | 12 | $562 | 0.0% | $47 |
| G2024 | Specimen collection for severe acute respiratory syndrome coronavirus 2 (sars-cov-2) (coronavirus disease [covid-19]) from an individual in a skilled nursing facility or by a laboratory on behalf... | 51 | $0 | 0.0% | $0 |
| G0481 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including | 147 | $0 | 0.0% | $0 |
| 87633 | Microbiology test — checking for infections (bacteria, viruses, fungi) | 30 | $0 | 0.0% | $0 |
| G0482 | Drug test(s), definitive, utilizing (1) drug identification methods able to identify individual drugs and distinguish between structural isomers (but not necessarily stereoisomers), including | 16 | $0 | 0.0% | $0 |
| 0202U | Medical service or procedure | 12 | $0 | 0.0% | $0 |
About This Data
This data comes from the HHS Medicaid Provider Spending dataset (opendata.hhs.gov). It shows payments made through Nevada Medicaid from 2018–2024. High payments do not mean a provider is doing anything wrong — some specialties naturally cost more, and busy providers see more patients. But unusually high numbers compared to peers can be worth a closer look.